We're #hiring a new Regional Specialist Liaison - Central in Chicago, Illinois. Apply today or share this post with your network.
Invivyd
Biotechnology Research
Waltham, Massachusetts 10,230 followers
On a mission to protect the vulnerable from serious viral infectious diseases
About us
Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage company is a biopharmaceutical company on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2. Leveraging state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering techniques, we are taking a platform-based approach to the continuous discovery and optimization of monoclonal antibody candidates designed to protect the vulnerable from serious viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
- Website
-
http://www.invivyd.com
External link for Invivyd
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
1601 Trapelo Rd
Suite 178
Waltham, Massachusetts 02451, US
Employees at Invivyd
Updates
-
We're #hiring a new Medical Director in Waltham, Massachusetts. Apply today or share this post with your network.
-
We're #hiring a new Director, Analytical Development in Waltham, Massachusetts. Apply today or share this post with your network.
-
We're #hiring a new Manager/Senior Manager, Medical Writing in Waltham, Massachusetts. Apply today or share this post with your network.
-
Meet Yuhong Zeng, our Director, Formulation and Drug Development. She shares why she chose Invivyd and why she stays.
-
-
Invivyd is on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people. If you’re passionate about protecting vulnerable people from the devastating consequences of circulating viral threats then check out our open positions! https://lnkd.in/edw2ghUr
-
We are pleased to announce that VYD222 shows continued in vitro neutralization activity in psuedovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants. Learn more: https://lnkd.in/e622YdzP
-
-
It's been a busy couple of weeks with Invivyd attending both #ASCO24 and #ATC2024Philly. We were pleased to present information about VYD222 (pemivibart), our investigational monoclonal antibody authorized for emergency use by the U.S. FDA.
-
-
We are thrilled to welcome Timothy Lee to the Invivyd team as our new Chief Commercial Officer. Tim brings a proven track record of leading commercial success, and his experience will be invaluable to our company as we continue advancing our platform and pipeline of anti-SARS-CoV-2 #mAbs designed to protect vulnerable populations from serious viral threats. Learn more about Tim: https://lnkd.in/gbcaWUiJ #weareinvivyd
-
-
On June 6th, we will participate in a fireside chat at the Jefferies Global Healthcare Conference at 3:00 p.m. ET. Tune in live or watch a replay: https://lnkd.in/gzDBfDYH #JefferiesHealthcare
-